Despite modest single-agent effects by IAG933 in a panel of seven HER2-amplified cell lines from various cancer indications, dose-dependent combination activity was seen for IAG933 with the HER2 inhibitor lapatinib (Fig. 5c), and prolonged combination activity after the end of treatment was observed in lengthier in vitro studies (Fig. 5d). This evidence concerns the gene ERBB2 and cancer.